A New Drug for Alzheimer's Disease

Clinical evaluation of BMS-984923 metabolism.

NIH-funded research Allyx Therapeutics INC. · NIH-11195550

This project is exploring a new medication called BMS-984923 that aims to protect brain connections in people with Alzheimer's disease.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionAllyx Therapeutics INC. NIH-funded
Lab location1 site (New Haven, UNITED STATES)
Project IDNIH-11195550 on NIH RePORTER

What this research studies

Alzheimer's disease causes memory loss by damaging the connections between brain cells, called synapses. This new medication, BMS-984923, is designed to stop this damage by targeting a specific protein pathway in the brain. Early laboratory and animal studies showed that this drug helped restore brain connections, improve brain activity, and bring memory performance back to normal. We are now conducting initial human studies to understand how this drug works in people and confirm its safety.

Who could benefit from this research

Good fit: Patients with Alzheimer's disease who meet specific criteria for early-stage clinical trials may be ideal candidates for future participation.

Not a fit: Patients seeking immediate therapeutic benefit may not find it in these early-stage studies, which primarily focus on safety and how the drug behaves in the body.

Why it matters

Potential benefit: If successful, this medication could slow or stop the progression of Alzheimer's disease by protecting brain connections, potentially improving memory and cognitive function.

How similar studies have performed: Previous laboratory and animal studies have shown promising results for this drug and its approach in protecting brain connections related to Alzheimer's disease.

Where this research is happening

New Haven, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's DiseaseAlzheimer's disease brain
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.